- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1776-260X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Correction to: SB8: A Bevacizumab Biosimilar ; volume:16 ; number:1 ; day:11 ; month:12 ; year:2020 ; pages:119 ; date:1.2021
Targeted oncology ; 16, Heft 1 (11.12.2020), 119, 1.2021
- Urheber
-
Syed, Yahiya Y.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11523-020-00783-1
- URN
-
urn:nbn:de:101:1-2021030612295925475509
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Syed, Yahiya Y.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
Correction to: MYL-1402O: A Bevacizumab Biosimilar
SB8: A Bevacizumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Correction to: GP2015: An Etanercept Biosimilar
Correction to: PB006: A Natalizumab Biosimilar